Canagliflozin Improves Erythropoiesis in Diabetes Patients with Anemia of Chronic Kidney Disease

Diabetes Technology & Therapeutics
Takashi MaruyamaMasanori Abe

Abstract

Background: We evaluated the erythropoietic effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, in type 2 diabetes patients with anemia of chronic kidney disease. Methods: Nine diabetes patients were enrolled and administered 100 mg canagliflozin once a day for 12 weeks. The patients received fixed doses of conventional antidiabetic drugs and renin-angiotensin system inhibitors for 8 weeks before enrollment; these drugs were continued during the study. Endpoints were changes in erythropoiesis parameters, including erythrocyte and reticulocyte count, hemoglobin, hematocrit, and serum erythropoietin (EPO) concentration from baseline to 12 weeks. All variables were measured every 2 weeks. Results: Serum EPO concentration increased by 38 [15-62]% (P = 0.043) between baseline and 2 and 4 weeks. Reticulocyte count transiently increased at 2 weeks. Erythropoiesis occurred after 2 weeks of canagliflozin treatment. Erythrocyte count (from 386 ± 36 × 104/μL to 421 ± 36 × 104/μL; P = 0.0009), hemoglobin (from 11.8 ± 0.6 g/dL to 12.9 ± 1.1 g/dL; P = 0.0049), and hematocrit (from 37.1 ± 2.3% to 40.4 ± 3.2%; P = 0.002) increased from baseline to study completion. Although there were no significant changes in transferri...Continue Reading

References

Jun 29, 2002·Journal of the American Society of Nephrology : JASN·Christian RosenbergerKai-Uwe Eckardt
Apr 12, 2005·Advances in Chronic Kidney Disease·M C ThomasM E Cooper
Nov 18, 2005·Journal of the American Society of Nephrology : JASN·Masaomi Nangaku
Mar 24, 2006·American Journal of Physiology. Renal Physiology·Volker H Haase
Apr 3, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Seiichi MatsuoUNKNOWN Collaborators developing the Japanese equation for estimated GFR
Oct 9, 2012·Current Opinion in Nephrology and Hypertension·Muralikrishna Gangadharan KomalaAmanda Mather
May 15, 2013·Diabetes, Obesity & Metabolism·H J Lambers HeerspinkJ List
Mar 31, 2015·Clinical Journal of the American Society of Nephrology : CJASN·Michael Zeisberg, Raghu Kalluri
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Nov 18, 2015·Current Opinion in Nephrology and Hypertension·Aleksandra Novikov, Volker Vallon
Jan 15, 2016·American Journal of Physiology. Renal Physiology·Anita T LaytonAurélie Edwards
Mar 2, 2016·The Journal of Clinical Investigation·Navid M FarsijaniVolker H Haase
Nov 2, 2016·Journal of the American Society of Nephrology : JASN·Rongpei LanManjeri A Venkatachalam
Jun 12, 2016·Diabetes Care·Ele FerranniniEric Mayoux
Jun 21, 2018·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Hiroyuki TakashimaMasanori Abe

❮ Previous
Next ❯

Citations

Feb 4, 2021·Heart Failure Reviews·Maja NikolicVladimir Jakovljevic
Feb 1, 2020·Journal of the American College of Cardiology·Thomas A Zelniker, Eugene Braunwald
Jan 20, 2021·Diabetes, Obesity & Metabolism·Robert J Chilton
Feb 23, 2021·European Journal of Heart Failure·Kieran F DochertyUNKNOWN DAPA-HF Investigators and Committees
Mar 30, 2021·Kidney International Supplements·Ritesh Raichoudhury, Bruce S Spinowitz
Mar 30, 2021·Kidney International Supplements·Peter A McCullough
May 19, 2021·Journal of Cardiovascular Pharmacology·Georgia AnastasiouEvangelos Liberopoulos
Aug 8, 2021·Drugs·Lucia Del VecchioSimonetta Genovesi
Oct 1, 2021·Circulation Journal : Official Journal of the Japanese Circulation Society·Hiroyuki TsutsuiUNKNOWN Japanese Circulation Society and the Japanese Heart Failure Society Joint Working Group
Nov 18, 2021·Critical Reviews in Clinical Laboratory Sciences·Reza Mohebi, James L Januzzi
Nov 20, 2021·Journal of Diabetes Investigation·Miho MurashimaTakayuki Hamano
Aug 10, 2021·Cardiovascular & Hematological Agents in Medicinal Chemistry·Mauro GittoGiulio G Stefanini

❮ Previous
Next ❯

Methods Mentioned

BETA
amputation

Software Mentioned

JMP

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.